ImmunityBio, Inc.(IBRX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IBRX ImmunityBio, Inc.

已收盘 02-03 16:00:00 EST

6.33

+0.20

+3.26%

盘后6.30

-0.03-0.48%

19:59 EST

最高6.54	最低5.95	成交量2,118万
今开6.15	昨收6.13	日振幅9.54%
总市值62.35亿	流通市值12.28亿	总股本9.85亿
成交额1.32亿	换手率10.92%	流通股本1.94亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"IBRX","market":"US","secType":"STK","nameCN":"ImmunityBio, Inc.","latestPrice":6.33,"timestamp":1770152400000,"preClose":6.13,"halted":0,"volume":21175106,"hourTrading":{"tag":"盘后","latestPrice":6.2999,"preClose":6.33,"latestTime":"19:59 EST","volume":280665,"amount":1769764.3153,"timestamp":1770166775533,"change":-0.0301,"changeRate":-0.004755,"amplitude":0.018957},"delay":0,"changeRate":0.03262642740619905,"floatShares":194000000,"shares":984965179,"eps":-0.415322,"marketStatus":"已收盘","change":0.2,"latestTime":"02-03 16:00:00 EST","open":6.145,"high":6.535,"low":5.95,"amount":131906701.883874,"amplitude":0.095432,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.415322,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1770195600000},"marketStatusCode":5,"adr":0,"listingDate":1438056000000,"exchange":"NASDAQ","adjPreClose":6.13,"preHourTrading":{"tag":"盘前","latestPrice":6.19,"preClose":6.13,"latestTime":"09:29 EST","volume":138503,"amount":849740.5031328,"timestamp":1770128979910,"change":0.06,"changeRate":0.009788,"amplitude":0.017945},"postHourTrading":{"tag":"盘后","latestPrice":6.2999,"preClose":6.33,"latestTime":"19:59 EST","volume":280665,"amount":1769764.3153,"timestamp":1770166775533,"change":-0.0301,"changeRate":-0.004755,"amplitude":0.018957},"volumeRatio":0.692292,"impliedVol":1.4161,"impliedVolPercentile":0.9004},"requestUrl":"/m/hq/s/IBRX/wiki","defaultTab":"wiki","newsList":[{"id":"1120348816","title":"ImmunityBio启动ANKTIVA®联合CAR-NK细胞疗法2期临床试验，探索无化疗方案治疗惰性淋巴瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1120348816","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120348816?lang=zh_cn&edition=full","pubTime":"2026-02-02 20:08","pubTimestamp":1770034122,"startTime":"0","endTime":"0","summary":"ImmunityBio, Inc.（纳斯达克代码：IBRX）近日宣布启动一项2期临床研究，评估其核心产品ANKTIVA®（通用名resq215b）与嵌合抗原受体自然杀伤细胞（CAR-NK）疗法联合用于惰性淋巴瘤治疗的潜力。该试验的创新之处在于采用完全无化疗的治疗策略，旨在通过生物免疫疗法精准靶向肿瘤细胞，减少传统化疗带来的毒副作用。若研究结果积极，有望为惰性淋巴瘤患者提供更安全、耐受性更高的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRX","BK4139"],"gpt_icon":0},{"id":"1198499689","title":"ImmunityBio, Inc.临床试验：三名受试者出现疑似与实验疗法相关的严重不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1198499689","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198499689?lang=zh_cn&edition=full","pubTime":"2026-01-23 20:03","pubTimestamp":1769169797,"startTime":"0","endTime":"0","summary":"在ImmunityBio, Inc.进行的一项临床研究中，有三名参与试验的受试者报告出现了严重不良事件。目前，这些事件被怀疑与该公司所研发的实验性疗法存在关联。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRX","BK4139"],"gpt_icon":0},{"id":"1154477526","title":"ImmunityBio公布：接受Anktiva®联合CAR-NK无化疗疗法的复发性胶质母细胞瘤患者中位总生存期尚未达到，淋巴细胞减少症得以逆转","url":"https://stock-news.laohu8.com/highlight/detail?id=1154477526","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154477526?lang=zh_cn&edition=full","pubTime":"2026-01-23 20:01","pubTimestamp":1769169688,"startTime":"0","endTime":"0","summary":"ImmunityBio公司最新报告显示，在采用Anktiva®联合CAR-NK细胞疗法的复发性胶质母细胞瘤患者中，中位总生存期数据尚未达到可统计的终点。这一无化疗治疗方案不仅展现出延长生存期的潜力，更值得注意的是，患者先前存在的淋巴细胞减少症出现了显著逆转。\n该疗法通过激活患者自身的免疫系统对抗肿瘤，为传统治疗手段效果有限的脑癌患者提供了新的希望。淋巴细胞计数的恢复表明免疫功能得到改善，这可能为提升抗肿瘤疗效奠定基础。\n研究结果凸显了Anktiva®与CAR-NK联合疗法的双重优势：既可能延长生存期，又能逆转化疗常见副作用带来的免疫抑制状态。这一突破性进展为晚期脑癌治疗开辟了全新路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRX"],"gpt_icon":0},{"id":"1124337225","title":"异动解读 | ImmunityBio盘中大跌10.11%，因FDA要求提供膀胱癌药物更广泛应用信息","url":"https://stock-news.laohu8.com/highlight/detail?id=1124337225","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124337225?lang=zh_cn&edition=full","pubTime":"2026-01-21 22:33","pubTimestamp":1769005984,"startTime":"0","endTime":"0","summary":"ImmunityBio, Inc.（IBRX）今日盘中股价大跌10.11%，引发了市场的广泛关注。消息面上，美国食品和药物管理局（FDA）要求该公司提供更多信息，以支持其膀胱癌药物Anktiva在更广泛患者群体中的使用申请。这一请求可能引发了投资者对审批进程延迟或额外要求的担忧，从而导致股价大幅下跌。ImmunityBio表示，FDA并未要求进行新的临床试验，但需要补充某些信息以支持重新提交的申请。公司计划在未来30天内提交所需信息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["IBRX"],"gpt_icon":0},{"id":"1123640335","title":"异动解读 | ImmunityBio盘前大跌5.09%，因FDA要求提供膀胱癌药物更广泛应用信息","url":"https://stock-news.laohu8.com/highlight/detail?id=1123640335","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123640335?lang=zh_cn&edition=full","pubTime":"2026-01-21 21:24","pubTimestamp":1769001860,"startTime":"0","endTime":"0","summary":"ImmunityBio, Inc.（IBRX）今日盘前股价大跌5.09%，引起了市场的广泛关注。消息面上，美国食品和药物管理局（FDA）要求该公司提供更多信息，以支持其膀胱癌药物Anktiva在更广泛患者群体中的使用申请。这一请求可能引发了投资者对审批进程延迟或额外要求的担忧，从而导致股价下跌。ImmunityBio表示，FDA并未要求进行新的临床试验，但需要补充某些信息以支持重新提交的申请。公司计划在未来30天内提交所需信息。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["IBRX"],"gpt_icon":0},{"id":"1160682901","title":"异动解读 | ImmunityBio夜盘大跌5.25%，因FDA要求提供膀胱癌药物更广泛应用信息","url":"https://stock-news.laohu8.com/highlight/detail?id=1160682901","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160682901?lang=zh_cn&edition=full","pubTime":"2026-01-21 09:32","pubTimestamp":1768959164,"startTime":"0","endTime":"0","summary":"ImmunityBio, Inc.（IBRX）今日夜盘股价大跌5.25%，引起了市场的关注。消息面上，美国食品和药物管理局（FDA）要求该公司提供更多信息，以支持其膀胱癌药物Anktiva在更广泛患者群体中的使用申请。这一请求可能引发了投资者对审批进程延迟或额外要求的担忧，从而导致股价下跌。ImmunityBio表示，FDA并未要求进行新的临床试验，但需要补充某些信息以支持重新提交的申请。公司计划在未来30天内提交所需信息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["IBRX"],"gpt_icon":0},{"id":"1176958641","title":"异动解读 | ImmunityBio盘中大涨31.34%，因膀胱癌药物Anktiva获FDA进一步审核","url":"https://stock-news.laohu8.com/highlight/detail?id=1176958641","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176958641?lang=zh_cn&edition=full","pubTime":"2026-01-20 23:10","pubTimestamp":1768921821,"startTime":"0","endTime":"0","summary":"ImmunityBio（IBRX）今日盘中股价大幅上涨31.34%，成为市场焦点。消息面上，该公司宣布准备重新向美国食品药品监督管理局（FDA）提交申请，寻求批准其膀胱癌药物Anktiva用于更广泛的患者群体。FDA要求提供更多信息但未要求新试验，公司计划30天内完成提交。长期数据显示，几乎所有接受Anktiva联合卡介苗治疗的患者存活至少三年，超80%保留膀胱避免手术。这一进展显著提升了市场对药物商业化前景的预期。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"c6432e252784cc64192d8c0a1d7cc58c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["IBRX"],"gpt_icon":0},{"id":"1182603474","title":"异动解读 | ImmunityBio盘中大涨29.50%，多款癌症疗法临床试验数据积极","url":"https://stock-news.laohu8.com/highlight/detail?id=1182603474","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182603474?lang=zh_cn&edition=full","pubTime":"2026-01-16 23:14","pubTimestamp":1768576471,"startTime":"0","endTime":"0","summary":"ImmunityBio, Inc.今日盘中大涨29.50%，创下近期新高。消息面上，公司公布了多款癌症疗法的积极临床试验数据。其中，针对一线BCG初治非肌层浸润性膀胱癌的Anktiva与BCG联合疗法中期分析结果积极，患者入组人数超出预期。公司还公布了罕见血癌疗法的积极数据，进一步提振了投资者信心。这些突破性成果不仅展现了ImmunityBio在癌症治疗领域的创新能力，也为后续监管审批和商业化奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["IBRX"],"gpt_icon":0},{"id":"1189285578","title":"ImmunityBio股价盘前飙升23.8%，公司公布罕见血癌疗法积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1189285578","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189285578?lang=zh_cn&edition=full","pubTime":"2026-01-16 20:20","pubTimestamp":1768566020,"startTime":"0","endTime":"0","summary":"ImmunityBio, Inc. (纳斯达克代码: IBRX) 股价在盘前交易时段大幅攀升23.8%，此前该公司公布了其针对一种罕见血癌的疗法的临床试验结果。\n这一显著涨幅反映了市场对该疗法积极数据的乐观反应。公司披露的详细结果显示，其在研疗法在临床试验中取得了令人鼓舞的成效，为治疗这种罕见血液癌症带来了新的希望。\n消息公布后，投资者信心得到提振，推动该股在盘前交易中表现强劲。市场正密切关注该疗法的后续进展及其对ImmunityBio未来业绩的潜在影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRX","BK4139"],"gpt_icon":0},{"id":"1152780615","title":"ImmunityBio推进一线BCG初治NMIBC项目 患者入组超预期且Anktiva®联合BCG中期分析结果积极","url":"https://stock-news.laohu8.com/highlight/detail?id=1152780615","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152780615?lang=zh_cn&edition=full","pubTime":"2026-01-16 20:09","pubTimestamp":1768565391,"startTime":"0","endTime":"0","summary":"ImmunityBio公司宣布，其针对一线BCG初治非肌层浸润性膀胱癌的研发项目取得显著进展。目前患者入组人数已超出预期目标，同时Anktiva®与BCG联合疗法的中期分析显示出积极结果。这一里程碑为后续临床开发奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRX"],"gpt_icon":0},{"id":"1117568591","title":"FDA要求的中期分析显示：Anktiva联合BCG疗法显著延长完全缓解持续时间","url":"https://stock-news.laohu8.com/highlight/detail?id=1117568591","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117568591?lang=zh_cn&edition=full","pubTime":"2026-01-16 20:03","pubTimestamp":1768565029,"startTime":"0","endTime":"0","summary":"ImmunityBio, Inc.近期公布的一项由美国食品药品监督管理局（FDA）要求进行的中期分析结果显示，其研发的Anktiva联合BCG（卡介苗）治疗方案在临床试验中表现出统计学上显著的更长完全缓解持续时间。\n这一发现为膀胱癌等疾病的治疗提供了新的希望，凸显了联合疗法在提升患者临床获益方面的潜力。数据进一步证实，Anktiva与BCG的组合可能改善患者的长期治疗效果，为后续监管审批和临床应用奠定重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRX"],"gpt_icon":0},{"id":"2603962227","title":"Immunitybio, Inc.盘中异动 股价大涨5.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603962227","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603962227?lang=zh_cn&edition=full","pubTime":"2026-01-15 22:32","pubTimestamp":1768487535,"startTime":"0","endTime":"0","summary":"北京时间2026年01月15日22时32分，Immunitybio, Inc.股票出现波动，股价快速拉升5.30%。Immunitybio, Inc.股票所在的生物技术行业中，整体涨幅为0.24%。Immunitybio, Inc.公司简介：ImmunityBio Inc是一家综合性临床阶段生物技术公司，致力于发现、开发和商业化下一代免疫和细胞疗法，以增强自然免疫系统，从而驱动和维持免疫反应。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011522321597a1fc59&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011522321597a1fc59&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBRX","BK4139"],"gpt_icon":0},{"id":"1151783482","title":"沙特FDA加速批准ImmunityBio的Anktiva®联合检查点抑制剂治疗转移性非小细胞肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1151783482","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151783482?lang=zh_cn&edition=full","pubTime":"2026-01-14 21:36","pubTimestamp":1768397772,"startTime":"0","endTime":"0","summary":"沙特食品药品监督管理局（FDA）已对ImmunityBio, Inc.（纳斯达克代码：IBRX）旗下免疫疗法药物Anktiva®授予加速审批资格，批准其与检查点抑制剂联合用于治疗转移性非小细胞肺癌（NSCLC）患者。此项决定标志着该创新组合疗法在沙特阿拉伯监管流程中的关键进展，为晚期肺癌患者提供了新的潜在治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRX","BK4139"],"gpt_icon":0},{"id":"1121956771","title":"ImmunityBio公司Anktiva针对BCG初治NMIBC患者的随机试验入组进度超前 预计2026年第二季度完成全部入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1121956771","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121956771?lang=zh_cn&edition=full","pubTime":"2026-01-14 21:33","pubTimestamp":1768397603,"startTime":"0","endTime":"0","summary":"ImmunityBio公司宣布，其针对BCG初治型非肌层浸润性膀胱癌患者开展的Anktiva随机试验，目前患者入组进度较原计划大幅超前。根据最新时间表，这项重要临床研究预计将于2026年第二季度完成全部患者招募工作。\n该试验旨在评估Anktiva在BCG未接受过的NMIBC患者群体中的疗效与安全性。研究进度的加速推进，为早日获得关键临床数据奠定了坚实基础，也反映出医疗界对该创新疗法的积极参与和高度期待。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRX","BK4139"],"gpt_icon":0},{"id":"1159820089","title":"沙特药监局加速批准ImmunityBio的Anktiva®用于治疗伴有原位癌的非肌层浸润性膀胱癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1159820089","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159820089?lang=zh_cn&edition=full","pubTime":"2026-01-14 21:30","pubTimestamp":1768397421,"startTime":"0","endTime":"0","summary":"沙特食品和药物管理局（Saudi FDA）已对ImmunityBio, Inc.（纳斯达克代码：IBRX）旗下创新疗法Anktiva®予以加速审批通过。该药物获批适应症为伴随原位癌（Carcinoma in-Situ）的非肌层浸润性膀胱癌（NMIBC）治疗，标志着中东地区患者迎来了新的免疫治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRX","BK4139"],"gpt_icon":0},{"id":"1133524109","title":"ImmunityBio公布积极数据：Anktiva®联合检查点抑制剂展现淋巴细胞激活效应，为非小细胞肺癌治疗提供新方向","url":"https://stock-news.laohu8.com/highlight/detail?id=1133524109","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133524109?lang=zh_cn&edition=full","pubTime":"2026-01-13 21:31","pubTimestamp":1768311075,"startTime":"0","endTime":"0","summary":"ImmunityBio, Inc.近日发布重要临床研究结果，证实其核心产品Anktiva在与检查点抑制剂联合应用时，可显著激活淋巴细胞活性，针对非小细胞肺癌患者展现出潜在治疗价值。研究数据显示，Anktiva作为一种淋巴细胞刺激剂，能够有效增强免疫系统对癌细胞的识别与攻击能力。这一成果有望为晚期非小细胞肺癌患者提供更个性化和有效的治疗选择。目前，ImmunityBio正积极推进相关临床方案的优化与后续研究，力求早日将这一创新疗法推向市场，惠及全球患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRX"],"gpt_icon":0},{"id":"1178758921","title":"ImmunityBio修订文件获SEC批准 授权增发4.5997亿美元股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1178758921","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178758921?lang=zh_cn&edition=full","pubTime":"2025-12-29 19:16","pubTimestamp":1767006984,"startTime":"0","endTime":"0","summary":"根据最新提交给美国证券交易委员会（SEC）的修正案文件，生物技术公司ImmunityBio, Inc.已获得授权，将根据补充条款额外发行价值达4.5997亿美元的股份。这一举措标志着公司在资本运作方面迈出重要一步。\n该修正案进一步明确了股份发行的具体条款和条件，为公司的融资计划提供了更灵活的操作空间。此次增发将有助于ImmunityBio强化资金储备，支持其在免疫疗法领域的研发投入和业务拓展。\n市场分析人士指出，此类资本扩充行为通常反映了企业对未来发展的信心，也可能预示着后续重大研发项目或商业合作的推进。不过，具体资金用途及发行时间表仍需关注公司后续披露的详细信息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRX","BK4139"],"gpt_icon":0},{"id":"1108392616","title":"ImmunityBio获得欧洲药品管理局的条件性市场授权推荐，用于非肌肉侵袭性膀胱癌原位癌的Anktiva®与BCG联合治疗——在欧洲的首次","url":"https://stock-news.laohu8.com/highlight/detail?id=1108392616","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108392616?lang=zh_cn&edition=full","pubTime":"2025-12-12 19:10","pubTimestamp":1765537813,"startTime":"0","endTime":"0","summary":"ImmunityBio获得欧洲药品管理局的条件性市场授权推荐，用于非肌肉侵袭性膀胱癌原位癌的Anktiva®与BCG联合治疗——在欧洲的首次","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRX","BK4139"],"gpt_icon":0},{"id":"1109214275","title":"受强劲需求推动，ImmunityBio公布单位增长467%及销售额7500万美元，同比增长434%","url":"https://stock-news.laohu8.com/highlight/detail?id=1109214275","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109214275?lang=zh_cn&edition=full","pubTime":"2025-11-05 11:12","pubTimestamp":1762312333,"startTime":"0","endTime":"0","summary":"受强劲需求推动，ImmunityBio公布单位增长467%及销售额7500万美元，同比增长434%","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRX"],"gpt_icon":0},{"id":"2574413881","title":"Immunitybio, Inc.盘中异动 股价大跌5.10%报2.40美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2574413881","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574413881?lang=zh_cn&edition=full","pubTime":"2025-10-10 01:53","pubTimestamp":1760032408,"startTime":"0","endTime":"0","summary":"北京时间2025年10月10日01时53分，Immunitybio, Inc.股票出现波动，股价快速跳水5.10%。截至发稿，该股报2.40美元/股，成交量655.121万股，换手率0.69%，振幅5.53%。Immunitybio, Inc.股票所在的生物技术行业中，整体跌幅为0.16%。Immunitybio, Inc.公司简介：ImmunityBio Inc是一家综合性临床阶段生物技术公司，致力于发现、开发和商业化下一代免疫和细胞疗法，以增强自然免疫系统，从而驱动和维持免疫反应。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251010015328a4588cd1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251010015328a4588cd1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IBRX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immunitybio.com","stockEarnings":[{"period":"1week","weight":-0.0129},{"period":"1month","weight":2.0347},{"period":"3month","weight":1.9471},{"period":"6month","weight":1.5756},{"period":"1year","weight":0.7768},{"period":"ytd","weight":2.096}],"compareEarnings":[{"period":"1week","weight":0.0039},{"period":"1month","weight":0.0179},{"period":"3month","weight":0.0299},{"period":"6month","weight":0.099},{"period":"1year","weight":0.1555},{"period":"ytd","weight":0.0198}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"ImmunityBio, Inc.于2002年10月7日在伊利诺伊州ZelleRx Corporation公司的名义下注册成立，于2010年1月22日，公司更名为Conkwest股份有限公司。ImmunityBio是一家领先的晚期免疫治疗公司，可激活先天和适应性免疫系统，以治疗肿瘤学和传染病领域内严重未满足的需求。公司是一家领先的临床剂型的现成自然杀伤细胞疗法生产商，记忆NK细胞，连同抗体细胞因子融合蛋白、白蛋白结合化学免疫调节剂和疫苗载体的综合平台。通过结合这些NK、巨噬细胞和T细胞激活平台，该公司相信ImmunityBio在免疫治疗领域处于领先地位，具有跨越多种肿瘤类型和传染病的后期临床开发。","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":0.219152},{"month":2,"riseRate":0.454545,"avgChangeRate":0.022634},{"month":3,"riseRate":0.3,"avgChangeRate":-0.083879},{"month":4,"riseRate":0.5,"avgChangeRate":0.021643},{"month":5,"riseRate":0.4,"avgChangeRate":0.054052},{"month":6,"riseRate":0.3,"avgChangeRate":0.132356},{"month":7,"riseRate":0.4,"avgChangeRate":-0.029239},{"month":8,"riseRate":0.272727,"avgChangeRate":-0.110134},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.03348},{"month":10,"riseRate":0.454545,"avgChangeRate":0.029893},{"month":11,"riseRate":0.636364,"avgChangeRate":0.121867},{"month":12,"riseRate":0.363636,"avgChangeRate":0.048951}],"exchange":"NASDAQ","name":"ImmunityBio, Inc.","nameEN":"ImmunityBio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ImmunityBio, Inc.(IBRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ImmunityBio, Inc.(IBRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ImmunityBio, Inc.,IBRX,ImmunityBio, Inc.股票,ImmunityBio, Inc.股票老虎,ImmunityBio, Inc.股票老虎国际,ImmunityBio, Inc.行情,ImmunityBio, Inc.股票行情,ImmunityBio, Inc.股价,ImmunityBio, Inc.股市,ImmunityBio, Inc.股票价格,ImmunityBio, Inc.股票交易,ImmunityBio, Inc.股票购买,ImmunityBio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ImmunityBio, Inc.(IBRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ImmunityBio, Inc.(IBRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}